LIVE: HHS Announces FDA Approval Pathway for Individualized Therapies

Live News Network
1.4K followers
1 Video View·Feb 23, 2026
The Department of Health and Human Services (HHS) announces the FDA’s approval pathway for individualized drug and biologics therapies at 11:30 a.m. ET on Feb. 23.
He's in the hospital. Baby KJ came home. That's not just a recovery. It is a medical miracle.
When I heard KJ's story, I directed HHS and the FDA to move quickly to ensure that this breakthrough
technology would not remain a one-time medical miracle.
Every child facing rare genetic disease deserves the same kind of treatment that KJ got.
Please join me in recognizing two of the physicians who made that breakthrough possible,
Dr. Kiran Musunuru and Dr. Rebecca Ahrens-Nicholas from Children's Hospital of Philadelphia.
I also want to recognize some of the congressional leaders who helped us to make this happen,
who've driven this agenda for a long time on Capitol Hill. One of them, Senator Roger Marshall
from Kansas, who's a physician, and who I consider not only a friend but a partner in all of the
MAHA agenda. And then Nancy Harshberger, the congresswoman from Tennessee, who's also a
pharmacist. And thank you so much for your activism on this issue and your very strong advocacy.
And then Nick Begich, the congressman, the sole congressman from Alaska,
who's helped drive this issue in his wonderful life, Darna, who is also a pharmacist from Alaska.
Thank you for being here today, and thank you for your visionary leadership
in making these kind of treatments available for every American. And to the physicians and
researchers, advocates, and families in this room, your persistence brought us to this moment.
Today we turn that persistence into policy. The FDA releases draft guidance establishing a new
pathway to approval for individualized therapy for rare genetic disorders. And we're calling
this the plausible mechanism framework. This framework aligns regulation with biology.
For ultra-rare conditions, randomized control trials are often and mostly always just not
feasible. Under the framework that we're announcing today, one well-controlled
clinical investigation supported by confirmatory evidence can support approval. For decades,
families heard the same thing. There are not enough patients. The approval will take too long.
You just have to wait for the science to catch up with your child. That ends today.
A disease with a hundred the same mutations in the same gene will no longer require a hundred
clinical trials. When biology is clear and the science is sound, we will evaluate therapies
based upon strong evidence and not arbitrary barriers. Individualized medicine is no longer
theoretical. It's a child breathing on their own. It's a mother sleeping through the night.
It's a family planning for a future instead of fearing one. To the doctors here,
bring us rigorous science. Define clear endpoints. Collect strong data. Move with
discipline and speed, and we will move with you. The parents here, you endure delay from a system
not built for diseases this rare. We are ending that delay. You should never have had to fight
the government while fighting for your child's life. We will insist on transparency. We will
require long-term safety monitoring, and we will act with urgency. Medicine advances one patient
at a time, and regulation has to keep pace. This reform builds on other decisive actions that
HHS has taken for Americans with rare diseases. A few months ago, HHS added rare diseases,
Duchenne muscular dystrophy, and metachromatic leukodystrophy to the recommended universal
screening pattern for newborns. That decision allows physicians to identify,
diagnose, and begin treatment sooner when the time matters the most. The Centers for Medicaid and
Medicare Services LNG therapy access model expands access to life-saving therapies by securing
discounts and outcome-based rebates for states with treatments that deliver results.
This is about more than policy. It's about people. You're going to hear today from Judy Stecker
about her son, Wheeler, the youngest CLN3 patient ever diagnosed.
Julie Vitarello is also with us today. In 2018, the first Trump administration
cleared the first medicine made for a single patient, Julia's eight-year-old daughter,
Mila. Her therapy, Milasen, opened up a new frontier. Mila's disease eventually progressed,
and in 2021, her big spirit left her body. What Julia began as a race to save her own daughter
became a movement to break the regulatory barriers for children with fatal genetic diseases.
We also recognize Gwen Traficant. When her husband, Jim, was diagnosed with a rare liver disease,
she stood behind him through two grueling treatments. Years later, her daughter, Ashley,
faced the same diagnosis and underwent two more. Her son, Jeremy, became a living donor to save his
sister's life. Today, Gwen chairs the Virginia Rare Disease Council and guides families through
a system that she knows firsthand. We stand now at an edge of a new era. Genome editing,
RNA therapies, mutation-specific medicines designed for individual patients.
Innovation without accountability destroys trust. Regulation without flexibility destroys hope.
We reject both extremes. We choose innovation and accountability. We choose speed and safety.
We choose science and compassion. Together, we will accelerate cures, empower physicians,
heal patients, fuel innovation, and make America healthier. I now welcome FDA Commissioner Marty
McCary. Marty understands that innovation without accountability destroys trust,
and that regulation must keep pace with science. Under his leadership, the FDA is doing both.
Marty has been, in my view, the most important, the most effective FDA leader in history,
and I'm very, very glad to have him as a friend and a partner. Thank you, Marty, and welcome.
Thank you, Mr. Secretary. It's so great to be here and to reconnect with so many from the rare
disease community, members of Congress who have been waving a flag in the air advocating for this
issue. Turns out rare diseases are pretty common. 30 million Americans have a rare disease. That's
one in 11 people in our country. And for too long, they have been underappreciated,
underrecognized. The research has been underfunded, because our system is built for
common diseases, not for rare ones. And I've taken care of many patients with rare diseases.
And I'll tell you, it's hard. It's hard to look somebody in the eyes and say there's nothing out
there that we know of that we can offer you. It has an impact on your soul. They don't understand
that the market size is too small, and it doesn't incentivize companies. It doesn't make sense to
people, nor should it. When you're in that situation at the bedside, and I've been there
hundreds of times, you ask yourself, is there anything out there or anything humanly possible
that we can do differently? And that is the perspective that I bring to the FDA.
When people say, why are you doing so much stuff? That's why. Because they have been waiting for
too long without satisfying answers for many of these conditions. Historically, rare diseases have
been at the FDA an afterthought. Rigorous, elaborate standards so high, they're just not
practical for many of the therapies for rare diseases. But today, treatments for rare diseases
have powerful incentives, expedited reviews, tax credits for clinical trials, extended market
exclusivity, and a powerful incentive, if the drug is approved, a pot of gold of $100 to $200
million in the form of a transferable priority voucher. So we've come a long way.
Thanks to many of you who have been championing these ideas. Today, the majority of drugs we
approve at the FDA are for rare diseases. It is the majority of our resources. In December,
FDA's Center for Biologic Evaluation and Research hit a record number of approvals.
But we can't be satisfied. We can't let up. That's why we're pressing ahead.
Last month, we announced new manufacturing flexibilities for cell and gene therapies
to lower costs, cut the red tape, and speed up many of these potential cures. You don't have
to run three manufacturing batches routinely anymore, thanks to this announcement. We've
removed the long, onerous requirements for follow-up for people who get CAR T therapy.
We don't want investors scared away because of the high cost. We want investors to see the bright
promise of rare disease therapies. We announced last month at the JPMorgan Healthcare Conference
that we're embracing fully Bayesian statistics that are ideal for small populations and pull
in data from other trials to help make conclusions that's not just a p-value of 0.05 above or below.
It's not a frequentist dichotomous approach. We can learn from individual patients.
We've approved every single compassionate use right-to-try authorization that has come across
our desk. And we believe in both the spirit and letter of right-to-try. And thanks to Congress,
a few weeks ago, they passed and we were on the Hill actively pushing for this. The
Pediatric Priority Voucher Program. So it is renewed and signed into law just two and a half
weeks ago by President Trump. We're going to keep going. Today, we're announcing new guidance at the
FDA on the plausible mechanism pathway. What is a plausible mechanism pathway? It's common sense.
For the first time, the FDA is issuing guidance where giving an ultra rare disease therapy,
giving drug developers of ultra rare disease therapies, a path to accelerated or traditional
approval based on the experience of individuals. We can learn from individuals. I have learned
from individual patients of mine. And when you see something amazing right in front of your eyes,
that is a type of evidence. It's time that the FDA recognizes it.
So I want to thank all of you who have been pushing for this. And I want to thank
Tracy Beth Hogue, who leads our center called CEDAR. And she's going to come up now and share
a little bit with you. Thank you, Tracy. Hi, everyone. Thank you, Dr. McCary. I'm
Tracy Beth Hogue. I'm the acting director of CEDAR, the Center for Drug Evaluation
and Research. And today is a very exciting day for patients living with ultra rare diseases
in the community, all of you and across the world, the people that support them and want to see
effective cures and treatments for these patients who it's been a struggle to find effective
treatments and cures for in the past. But I want to let you know that during the fire drill
that I think it was not a real fire. I'm still not sure. I didn't see any flames. But
that I was discussing with two of the researchers here who have been foundational in the plausible
mechanism framework, Dr. Musunuru and Dr. Aarons, Nicholas, how we are going to operationalize the
plausible mechanism pathway at the FDA. They are the scientists who are behind the treatment of
ABKJ, who inspired the plausible mechanism pathway, as Secretary Kennedy just explained to
you. So what is the plausible mechanism pathway? The plausible mechanism pathway is a way for
treatments to get a special path to approval that uses the same standards for FDA approval as we've
always used. But these treatments, they treat a disease with a specific molecular or cellular
basis for the disease with a treatment that directly targets this molecular or cellular
or genetic basis. And then they are able to demonstrate evidence with this treatment that
they've been able to alter the basis of this disease and show a clinical response or some
sort of biochemical response that is different from that we would normally see with the natural
history of these diseases. And then with these ultra-rare diseases, we can look at them not just
as one individual disease, but as these researchers here and other researchers have been able to show
that we'll be able to look at these as a collection of diseases in potentially one clinical
trial, but that because they are similar treatments, be it genetic editing or antisense oligonucleotide
treatments, as we would see in my Center for Drug Evaluation and Research, where they use a similar
mechanism but treat different diseases, and thereby we can treat a larger patient population.
And so this really epitomizes what individualized medicine is, and it's so exciting to see this
happen. And what I was part of this effort in CDER and CBER cross-center effort to write this
plausible mechanism framework draft guidance, and it was very exciting to see our centers come
together and the enthusiasm that everyone had for this, because I think we sense together that
this is going to be a transformational draft guidance in the sense that it's going to inspire
industry to start developing these treatments in a way that we haven't seen before, and that
we all feel, and I know that the researchers up here today feel similarly, that the FDA is likely
going to be overwhelmed with applications for these treatments for these rare diseases. And
that's wonderful and exciting, and, you know, we're going to need to be creative in the way
that we meet this new demand, but this is such great news for patients and the family members
and communities living with patients with rare diseases. And so you've already heard a bit about
Baby KJ, who really inspired this plausible mechanism pathway, and so now I'm very excited
to introduce you to one of the researchers who was the first author of the paper in the New
England Journal of Medicine article outlining the treatment of Baby KJ, and I highly recommend that
you read that as well as the plausible mechanism framework in the New England Journal to better
understand this topic. And so the researcher that I'm going to introduce you to is Dr. Kieran
Musunuru from the University of Pennsylvania, and he is a distinguished professor at the University
of Pennsylvania and a practicing cardiologist, and has won multiple awards, and it's such an honor
to meet him and to introduce him, and he is going to tell you a bit more about the plausible
mechanism framework and genetic editing for ultra-rare diseases. Thank you, Dr. Musunuru.
Thank you so much for the very generous introduction, Dr. Hogue. It's a real privilege
for me to be here to speak to all of you on this occasion. I should note that I'm a physician
scientist and a practicing cardiologist, so even though this is a rare disease day event,
I want to start by talking about heart disease, the leading cause of death in the U.S.
To tackle that threat, my team created a genetic therapy to turn off a cholesterol gene in the
liver, permanently reduce cholesterol levels, and give lifelong protection against heart disease,
and this therapy is now showing signs of success in clinical trials. Now, the beauty of this kind
of therapy is that it has a small component that acts like a GPS. Switch the address in that GPS,
and the therapy will go to another gene and make a desired change. Otherwise, it's pretty
much the same therapy. So, as you've heard, in the summer of 2024, a baby boy named KJ was born
at the Hospital of the University of Pennsylvania, where I work. He immediately became deathly ill
from an ultra-rare disease called CPS1 deficiency, caused by a misspelling unique to him in one of
his genes in his liver. He was so close to death that there was actually serious discussions about
transitioning him to comfort care and allowing him to pass away peacefully, but his parents
rallied. He was moved across the street to the Children's Hospital of Philadelphia to receive
life-saving treatment, and with funding from the NIH, specifically the somatic cell genome editing
program, and working closely with the FDA, we were able to take that same heart disease genetic
therapy, just change the GPS address to point the therapy to KJ's broken gene, correct his unique
misspelling, turn the broken gene in his liver back on, and make him healthier. Although this was not a
cure, he is now thriving, growing well, full of insatiable curiosity and unbridled joy, and we
realized we could do this over and over again, individualizing the therapy to many patients with
liver-centered diseases by just changing the GPS address again and again, correcting each person's
misspelling, and so now we've turned this therapy into a whole platform, again with funding from the
NIH, working closely with the FDA that will position us to eventually launch a single
clinical trial for a whole set of liver-centered diseases, the urea cycle disorders. We'll be
continuing our work with the FDA using the plausible mechanism framework that's being
published today with a goal of getting to an approval of this platform as efficiently as
possible and getting individualized treatments for the urea cycle disorders to all the patients
in the U.S. who could benefit from them, but that's just the first step. We intend to expand this work
to many other liver-centered diseases, and as we go forward, we'll share our learnings with everyone
in the hope that when scientists develop technologies to get this kind of therapy
to many organs besides the liver, it will allow doctors to treat many, many rare diseases by
getting at their root causes. It will be a whole new medical subspecialty, interventional genetics,
and the goal will be to fix things early and give the gift of life to the tens of millions
of Americans who collectively suffer from rare diseases. They deserve nothing less,
and now it's my immense pleasure to introduce my good friend and colleague,
Dr. Rebecca Ernst-Nicholas of the Children's Hospital of Philadelphia. She's a physician
scientist like me. She co-led the development of KJ's therapy with me. We were equal partners. I'd
actually give her a little more of the credit. She's an extraordinary pediatrician and metabolic
disease expert who was part of KJ's care team. I'm so thankful to God every single day that I have
the privilege of working with her. Here's Becca. Thank you, and thank you for the kind introduction,
and I want to express my gratitude to everyone for allowing me to be here today and participate
in this important event. Every day, I have the privilege of caring for patients with rare diseases
and leading a team of scientists in my laboratory in collaboration with Kieran's group and others
to try and find solutions to help them. Unfortunately, our rare disease communities
face real uphill battles when it comes to developing new therapies. Small patient
populations and limited natural history data can make trials really hard to run.
Add regulatory uncertainty, high per patient development costs, and uneven access to
diagnostic testing and expert clinical care, and it's really easy to see why promising science
too often stalls before it reaches patients. The biggest hurdle, though, is moving beyond
a first-in-human trial to regulatory approval. Getting past that gap is what allows treatments
to become commercially available, reimbursed, and scaled so all patients who need them can access
them, not just those in a single small study. Since our work developing KJ's experimental
therapeutic was published, Kieran and I have received thousands of requests from desperate
families asking for our help. As a scientist, a physician, and a mom, this is heartbreaking. We
need to do better. This is why clear, pragmatic, consistent regulatory guidance is essential.
The types of individualized genetic therapies that we're trying to develop simply do not fit
in the traditional model of drug development. This is true for so many treatments for rare
and ultra-rare diseases, and we need these innovative regulatory frameworks that will
allow us to efficiently evaluate if these treatments are safe and if they work. However,
I do want to raise a challenge to all of us who hope to employ these novel frameworks.
With this opportunity will come great responsibility. When developing therapies
using this framework, every single piece of data from every patient is priceless. We already know
this in the world of rare diseases, but it will be even more true now. And I hope that we can
all proceed with radical transparency and share all that we learn, both the triumphs and the
struggles, as we build this field of interventional genetics. It's really the only way we will truly
honor our rare disease patients. It is an amazing time in the history of science and medicine.
Due to our robust tradition of federally funded science, we are the global leaders
in designing transformational, cutting-edge treatments that will make our population
healthier. And I'm really excited to see what comes next. And now I'm honored to introduce
Judy Stecker, who can explain firsthand why innovative frameworks like the one announced
today are so essential. In addition to her history of service here at HHS, she's done a heroic job
advocating for her son, Wheeler, a rare disease warrior. Thank you, Dr. Ahrens-Nicholas, for that
kind introduction. And I want to thank Secretary Kennedy, Commissioner McCary, Dr. Hogue, and the
department for inviting me to share my story. As we kick off Rare Disease Week, I also want to
recognize all the rare advocates and families, including my own here today. Court, Wheeler,
Reed, Mana, and Papa, you all make the rare disease community what it is. It was your advocacy
and your voices that gave me strength on my darkest day, Diagnosis Day, May 29, 2019.
On that day, I was told my son, Wheeler, just four weeks old, had CLN3 juvenile bat disease,
a rare genetic disease that will steal his vision, memory, mobility, and ultimately his life.
Unlike many rare families, we didn't have the diagnostic odyssey so many endure to figure
out what is happening to their child. Years earlier, my husband, Courtney, and I learned
we were carriers of this cruel disease. We spoke to families, countless experts, pastors, and priests.
We prayed, and we decided to explore IVF with pre-implantation genetic diagnosis.
After multiple miscarriages and failed cycles, we were told it was unlikely, if not impossible,
that we could conceive. But God has a plan, and he made a way. I ended up serving in the first
Trump administration here at HHS, and shortly into that role, against all odds and all efforts
to avoid it, I became pregnant. We knew the risk, but we had faith. But on that May day,
our lives were forever changed, and we began the journey that rare families face.
Not enough data, not enough treatments, not enough help, and not enough hope. I felt helpless.
What could I do? I reached out to colleagues at HHS, and soon our new family was at the NIH,
joining an existing natural history study, providing critical data to better understand
disease progression, and perhaps one day help prove a therapy's efficacy. Treatments, however,
would prove more difficult. I learned that the traditional drug development pathway,
requiring multi-million dollar trials spanning several years for drugs that treat the masses,
were simply unfeasible for rare diseases like Wheeler's. To reach the promise of modern science,
families like mine have had to build their own path until today. Through sheer will and
desperation, they raised millions of dollars hosting bake sales and golf tournaments,
finding scientists willing to develop a therapy, convince an institution to manufacture and
administer it. While this is tremendous, it puts incredible pressure on families who are already
juggling the challenges of a terminally ill child. And it only helps one child, one mutation,
and one desperate family at a time. This is not a sustainable path. It is a series of individual
acts of heroism by parents, doctors, and scientists. Parents like Julia Vitarello,
a fellow Batten disease mom, who just a year before Wheeler was born, worked with doctors,
scientists, and the FDA to develop a highly precise genetic medicine for her daughter Mila,
who had CLN7. Mila became the first person in the world to receive an individualized medicine.
Through tears, I shared our story, and Julia described the Herculean effort to get Mila
treated, connected me with experts, and shared her hope and vision that what was possible for Mila
could someday be a path possible for millions, including Mila. Years passed, but firsts build
on each other. And in early 2025, I read about baby KJ, the first person in the world to receive
an individualized CRISPR therapy. Families like mine have watched these scientific breakthroughs
outpace our ability to get life-saving treatments to our children because regulations have simply
not kept pace. But today, that is beginning to change. Today's announcement, the Plausible
Mechanism Framework, recognizes the unique nature and enormous opportunity of individualized
therapies to address the health crisis of severe and life-limiting genetic disease,
and that an innovative process can, in and of itself, potentially be a product.
This framework creates a commercially viable path to deliver hope, not one child at a time,
but at scale, and lead the world in genetic medicine. Shortly after my son was diagnosed,
a senior FDA career official, Lauren Silvas, came to visit me. She held Wheeler in her arms
and said to me, there always has to be a first, and there is no reason it can't be him.
Mila is a first. KJ is a first. This administration, this president, this secretary,
this commissioner, have proven that they have the courage and commitment to make firsts happen.
So to all those here and listening, government officials, researchers, payers and providers in
the biotech industry, there are 30 million possible firsts in this country. 15 million
of them are children, and one of them is mine. We need you all to work together to take today's
guidance and translate it into getting individualized treatments to patients.
They are waiting, and for many, time is running out. So let's get to work. Thank you.
Thank you so much to all of our incredible speakers. We will now open up for Q&A,
and I ask that you keep the questions to the topic of today, and that you say your full name and
outlet when you are called on. We have our girls here with the microphones, if you could speak
to those as well so we can get started. Yeah, go ahead. Thanks. Zach Brennan from Endpoints News.
I was curious, can you explain this seeming contradiction where you're embracing genome
editing and you're embracing CRISPR-based systems, but you're not embracing mRNA vaccines?
Is there a contradiction there? Well, I think that would be quite a stretch to say we're not
embracing mRNA vaccines. We've approved two mRNA vaccines at the beginning of my time.
I would love to see the data on mRNA helping patients with cancer in a number of conditions.
Our job is to review applications that come in the door, and if the data supports the claims
that want to be made, then we will approve that product. So we have a very clear mandate from
Congress, what's safe and effective, and so that's our task. Now, there was funding for
mRNA technology at HHS. That funding was pivoted to other causes, and I'll tell you why. It's not
because we don't believe in mRNA technology. It's because the companies that made mRNA vaccines made
over $50 billion. They can fund their own research. It doesn't have to be on the backs of American
taxpayers. We should be funding research that is otherwise not getting funded, that has no money
for funding, such as funding for bespoke conditions and rare diseases, conditions that have been
in the blind spots of modern medicine, and that's why that funding was pivoted. So it has nothing to
do with a view of this is a promising or this is not a promising technology. Our job as regulators
is to be a referee, and we just want to see good science. Thank you.
Good morning. My name is Kim Higbee. I'm a rare disease mom, and also I represent the Hope for
PDCD Foundation, and I'm just curious how this relates to like diseases and therapeutics that
are already in the regulatory pathway right now, like specifically our drug just got a CRL
that we are working for right now, and is it only limited to
like gene editing, or is this also for other therapies?
Hi. Thank you for that great question. So no, this is not, this pathway is not limited to only
gene editing. We actually outlined in the draft guidance how this will apply to, we specifically
list antisense oligonucleotides, but leave it open to other types of treatments, and I'll give the
example of a recent approval that we had in CDER for Zycubo, which addresses an underlying issue
of copper absorption in children with Mencke's disease, which is a genetic disease, and the
manufacturers were able to show increased survival compared to the well-known natural history of the
disease without a randomized control trial in a relatively small number of patients, and this is
a type of evidence that we're going to be looking for with the plausible mechanism pathway. When
you're able to show with a limited number of patients increased survival, better quality of
life, better, you know, laboratory outcomes, which we've never seen before in the history of the
disease, like with baby KJ ammonia levels decreasing by nearly 50 percent, and the baby being able to
live in an outpatient setting and essentially normal life, which is inconsistent with the
natural history of the disease that we've seen before, this is overwhelmingly compelling evidence
of efficacy, and we do see these with rare diseases, and this is what things that we have
seen in the past and what we'll be looking for with the plausible mechanism. Now with the plausible
mechanism, the timeline we're hoping is going to be sped up dramatically compared to what we've
seen in the past, where we'll be able to lump types of treatments together, and then we'll be able
to move seamlessly from IND to phase two and three trials, and so get cures to patients much more
quickly, but specific issues with applications, you know, we hope that we, for products, we hope
that we can also address in a timely manner, and I can't speak specifically to that application, but
this is, we're going to have the same standards approval of approval that we've had in the past,
but hopefully be able to approve things more rapidly and in a more orderly manner than we've
been doing previously with now with this plausible mechanism pathway. Thanks. We have Arthur right
here. Thank you. Secretary Kennedy, Dr. Casey Means will sit before the health committee on Wednesday.
What can Dr. Means do, if Senate confirmed, to move this innovation and rare disease therapies,
and what do you expect from her? President Trump said you've picked her as the Surgeon General
nominee. We've been waiting for a long time for Dr. Means to come on board. We're very, very
excited about her coming on board. She has an extraordinary capacity to communicate to the
Surgeon General. The Surgeon General is a moral authority for the public or a medical authority
for the public on a whole wide range of issues, and we've been waiting for a long time for her
presence. We're very excited about it, and I think she, hopefully she'll be on very, very soon.
Okay, right here on the end. Hi, my name is Miriam O'Day. I'm here today representing
individuals who have alpha-1 and trypsin deficiency. This is a rare form of COPD.
I have a two-part question. Number one, in the policy statement that you listed online for
plausible, it does not define what ultra-rare is. We know that rare is defined in statute as 200,000
or less, so will this policy be at the discretion of the FDA to be able to define what ultra-rare
is? Secondly, with all of the innovative pathways that have been introduced over the years,
they have all depended on urgent and unmet needs, and fortunately and unfortunately for individuals
with alpha-1, there are three therapies in the marketplace that are available for them,
and so flexible endpoints, clinical trial design, real-world evidence, these have not been used as
biomarkers, have not been used. CT densitometry, which could be used, have not been implemented in
expediting review for alpha-1 antitrypsin deficiency therapies.
So it's a great question about alpha-1 antitrypsin, and when we were writing the draft
guidance, we were very careful to leave it open-ended to not limit this to ultra-rare diseases
because that it is an arbitrary cutoff between rare and ultra-rare diseases, but this could
apply to any diseases, even common, if they meet the criteria for the plausible mechanism pathway,
the well-defined underlying etiology, a targeted treatment, and then evidence that the treatment
addresses that problem and shows the benefit that we would see that's not consistent with
the natural history of the disease. In terms of real-world evidence, I actually just mentioned
that approval that we had in CDER for Mencke's disease, and that was actually based on real-world
evidence, not a randomized clinical trial, and so when we're able to see that, as I said, the
disease course is different with the treatment than what we would see with the natural history
of the disease, that is really compelling evidence, especially when it's overall survival,
though we can also certainly look at other endpoints, which are also very important.
Isn't she amazing? We're aligned. You got to do what's common sense, and there's probably
very few diseases that are poster child for this issue, and I would put the alpha-antitrypsin
deficiency, and I've taken care of patients who have had it at front and center in that
underappreciated diagnoses with a whole host of medical implications, and if you look at a clinical
endpoint, there's a number to pick from, but we got to use common sense. We have to use common
sense, and that's what this day is all about. Can we use common sense? So the other point I wanted
to add, and the reason I stepped up is you also asked about real-world evidence. So in the past,
when we came to the FDA, we learned a lot. One of the things we learned that was standard of
care at the FDA is that to admit real-world evidence to the FDA, it had to meet a whole
bunch of criteria, requirements so onerous that only 12 drugs since 2011 had submitted any real
world evidence, and they'll tell you because the requirements were so complex. You had to
be able to, in the database, drill down to an individual patient's clinical data. Well,
that basically means you need informed consent, and that means you can't use the SEER database.
You can't use the Medicare database. You can't use the Swedish national database. You can't use
experiences that a physician has compiled over their experiences, multiple institutions.
What are we doing? So we changed that. We announced our intent to change that guidance. You submit
whatever you want. You submit any real-world evidence. If it's not good evidence, we'll let
you know, but at least allow drug developers to submit the experience in the real world.
Okay, we'll take one more right there at the end. Yep, thank you.
Hi there. Maisha here from Inside Health Policy. Just a few follow-ups on the announcement. So who
will conduct the review for these therapies, and is a separate review needed for each patient,
and what kind of follow-up will FDA do after patients get the treatment?
All right, I'll take this one too. Very good question. So who is going to conduct the review?
So this is going to be the reviewers in CBER and CDER who will conduct the review, and then can
you state your second question one more time just so I'm sure I answer it correctly?
Yeah, so very good question. So the way that our career staff in CBER is looking at this now based
on a publication that came out in December in, let me just get the name of the, in American
Journal of Human Genetics, and discussing with the review team there. We will likely be requiring
separate INDs, but they will be under an umbrella protocol or application, and then we'll be able to
take the INDs to phase two and phase three trials together. So we'll kind of combine treatments that
have a similar mechanism like genetic editing as described with AVKJ, but address different
mutations that cause different diseases, but be considered really under the same protocol
and clinical trial. All right, thank you everyone. We really appreciate you coming out
and safe travels home. Thank you.
